Upregulation of cathepsin D in the caudate nucleus of primates with experimental parkinsonism. by Yelamanchili, Sowmya V. et al.
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Journal Articles: Pharmacology & Experimental 
Neuroscience Pharmacology & Experimental Neuroscience 
7-21-2011 
Upregulation of cathepsin D in the caudate nucleus of primates 
with experimental parkinsonism. 
Sowmya V. Yelamanchili 
University of Nebraska Medical Center, syelamanchili@unmc.edu 
Amrita Datta Chaudhuri 
University of Nebraska Medical Center 
Claudia T. Flynn 
Scripps Research Institute 
Howard S. Fox 
University of Nebraska Medical Center, hfox@unmc.edu 
Follow this and additional works at: https://digitalcommons.unmc.edu/com_pen_articles 
 Part of the Medical Pharmacology Commons, and the Neurosciences Commons 
Recommended Citation 
Yelamanchili, Sowmya V.; Chaudhuri, Amrita Datta; Flynn, Claudia T.; and Fox, Howard S., "Upregulation of 
cathepsin D in the caudate nucleus of primates with experimental parkinsonism." (2011). Journal Articles: 
Pharmacology & Experimental Neuroscience. 6. 
https://digitalcommons.unmc.edu/com_pen_articles/6 
This Article is brought to you for free and open access by the Pharmacology & Experimental Neuroscience at 
DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Pharmacology & Experimental 
Neuroscience by an authorized administrator of DigitalCommons@UNMC. For more information, please contact 
digitalcommons@unmc.edu. 
RESEARCH ARTICLE Open Access
Upregulation of cathepsin D in the caudate
nucleus of primates with experimental
parkinsonism
Sowmya V Yelamanchili1, Amrita Datta Chaudhuri1, Claudia T Flynn2 and Howard S Fox1,3*
Abstract
Background: In Parkinson’s disease there is progressive loss of dopamine containing neurons in the substantia
nigra pars compacta. The neuronal damage is not limited to the substantia nigra but progresses to other regions
of brain, leading to loss of motor control as well as cognitive abnormalities. The purpose of this study was to
examine causes of progressive damage in the caudate nucleus, which plays a major role in motor coordination
and cognition, in experimental Parkinson’s disease.
Results: Using chronic 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine treatment of rhesus monkeys to model
Parkinson’s disease, we found a upregulation of Cathepsin D, a lysosomal aspartic protease, in the caudate nucleus
of treated monkeys. Immunofluorescence analysis of caudate nucleus brain tissue showed that the number of
lysosomes increased concurrently with the increase in Cathepsin D in neurons. In vitro overexpression of Cathepsin
D in a human neuroblastoma cell line led to a significant increase in the number of the lysosomes. Such
expression also resulted in extralysosomal Cathepsin D and was accompanied by significant neuronal death
associated with caspase activation. We examined apoptotic markers and found a strong correlation of Cathepsin D
overexpression to apoptosis.
Conclusions: Following damage to the substantia nigra resulting in experimental Parkinson’s disease, we have
identified pathological changes in the caudate nucleus, a likely site of changes leading to the progression of
disease. Cathepsin D, implicated in pathogenic mechanisms in other disorders, was increased, and our in vitro
studies revealed its overexpression leads to cellular damage and death. This work provides important clues to the
progression of Parkinson’s, and provides a new target for strategies to ameliorate the progression of this disease.
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Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disease. Apart from its genetic predis-
position, most cases arise sporadically and factors
including drugs and toxic chemicals have been demon-
strated to induce PD [1]. While medical (e.g. L-3,4-dihy-
droxypheylalanine, L-DOPA) and surgical (e.g. deep
brain stimulation) therapies have been effective in the
treatment of PD to a certain extent, nothing to date is
capable of arresting disease progression.
In PD, there is progressive loss of dopamine (DA)
containing neurons in the substantia nigra (SN) pars
compacta. Motor symptoms initially dominate the clini-
cal picture, and as the disease progresses cognitive
abnormalities are often evident [1,2]. While numerous
studies examine damage and neuronal loss in the SN,
other neuronal systems and brain regions are also
affected [3]; and the nature of this additional neuronal
damage is relatively unknown.
Understanding the dysregulation of genes and proteins
involved in neuronal dysfunction and disease progres-
sion can open avenues for new therapeutic targets in
PD. One main outflow tract from the SN is to the stria-
tum where the presynaptic dopaminergic terminals
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originating in the SN are lost [4]. To address other PD-
related changes in the striatum, we targeted the caudate
nucleus (CN), a part of the striatum that not only
receives dopaminergic input from the SN as well as the
ventral tegmental area but also glutaminergic projec-
tions from prefrontal associational and anterior cingu-
late limbic areas. Similar to other regions of the
striatum, the CN is involved in motor function and also
has an important role in cognition. Imaging studies have
linked abnormalities in the striatum to altered cognitive
executive functions in those with PD [5-9].
A common cord in many aspects of neuronal survival
is the lysosomal pathways [10]. The lysosomal proteases,
which play a key role in intracellular proteolysis and in
extracellular remodeling [11], are important in maintain-
ing homeostasis by exerting degradation and regulatory
functions. Lysosomal dysfunctions have been specifically
associated with degenerative phenomenon [12] as well
as with age-related neurological diseases [13]. Among
the most powerful hydrolytic enzymes in the lysosomes
are the cathepsins. Cathepsin D (Cat D) is the major
intracellular aspartic protease and is present in relatively
high concentrations within the lysosomes. Previous stu-
dies in a variety of cell systems such as endothelial cells,
T-lymphocytes and fibroblasts have shown that
increases in Cat D leads to apoptosis (reviewed in [14]).
Cat D upregulation has been associated with neurode-
generative disorders including Alzheimer’s disease (AD)
and its presence extracellularly in senile plaques was
clearly noted [15]. The upregulation of Cat D was
shown to occur at an early stage in experimental models
of AD leading to slow apoptosis of neurons [16]. There-
fore, we questioned whether deregulation of lysosomal
Cat D is involved in the progressive neuronal damage as
seen in PD, focusing on the CN.
We hypothesized that Cat D can act as a molecular
trigger for neuronal damage in CN. Using a chronic 1-
methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) trea-
ted rhesus monkey model, we assessed the expression
level of Cat D in CN followed by immunohistochemical
analysis on brain sections. Next, we performed in vitro
overexpression of Cat D and subsequently followed the




Monkeys are sensitive to the PD-like effects of MPTP
and have a good correspondence of brain function, neu-
rochemistry, and neuroanatomy to humans. In monkeys,
both acute and chronic dosing protocols can lead to a
PD-like disease. While the acute effects of high dose
MPTP in experimental animals can be dramatic, the
acute toxicity differs from the course of PD. In addition,
functional recovery can occur in a variety of dosing
protocols.
Chronic MPTP dosing cannot only lead to stable
motor deficits but also cognitive abnormalities as seen
in PD. In order to better mimic the chronic nature of
PD, we utilized a repeated low-dose protocol, in which
animals received a dose of 0.3-0.4 mg/kg MPTP on two
consecutive days, followed by assessment of stable
effects of the treatment at 3-4 weeks post-treatment.
Animals then received repeat dosing in order to achieve
a state of stable, mild functional deficits. Following
treatment, animals displayed behavioral changes (less
grooming and social interaction when housed with
another monkey and aggressiveness to humans) and
spent more time lying down. Some monkeys showed a
dramatically impaired performance on a bimanual
motor skills (BMS) task, with slower times to perform
the test or no interest at all.
Signs of PD-like disease were scored using the Kurlan
scale [17], considered to be the optimal clinical rating
scale for MPTP-induced Parkinsonism in macaques
[18]. Through this dosing and rating system, we induced
a state of mild stable Parkinsonism (Kurlan scores of 3-
6.5 persisting a minimum of 7 weeks following the last
dose, Table 1, Figure 1). Histopathological analysis of
the dorsal striatum clearly showed a profound decrease
in tyrosine hydroxylase (TyH) [Figure 2A (upper panel),
2B (upper panel)] as well as dopamine transporter
(DAT) [Figure 2A (middle panel), 2B (lower panel)]
staining in the MPTP-treated monkeys compared to
untreated controls, revealing persistent damage to the
pre-synaptic dopaminergic terminals from the SN.
Upregulation of Cat D mRNA and protein in MPTP-treated
monkey CN
In order to assess whether neurodegenerative mechan-
isms were ongoing in the CN long after the termination
of MPTP treatment, we assessed the expression of Cat
D. We first analyzed if Cat D is altered at the mRNA
level. We extracted RNA from CN of the MPTP treated
monkeys and quantified Cat D mRNA by quantitative
real-time PCR in comparison to caudate RNA from four
untreated control monkeys. We found a significant
increase (p < 0.05) in Cat D mRNA levels in chronically
MPTP-treated animals (Figure 3A).
Next, we investigated which cell types in CN show
increased production of Cat D protein expression. As
seen in Figure 3B, there is increased Cat D immunor-
eactivity in the neurons of MPTP-treated monkey CN.
Interestingly, there is increased staining in soma and
axonal cones. Intriguingly, this staining pattern has
been previously reported to be present in AD [15].
Furthermore, we examined co-localization of Cat D
and the neuronal marker MAP2 and ascertained that
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its increased expression is indeed in neurons (Figure
4A). Additionally, we examined if Cat D co-localizes
with IBA1, a microglial marker; however we did not
observe distinct expression of Cat D in microglial cells
(Figure 4B).
Proper regulation of cathepsin levels is important in
neurons, and upregulation as well as absence of cathe-
psins have considerable consequences on the mainte-
nance and function of nervous system. Lysosomal
proteases are rarely secreted outside the cells under
Table 1 MPTP-treated animal subjects
Animal Total MPTP (mg/kg) Weeks since first treatment Weeks since last dose Final Kurlan score
543 4.1 31 7 3
547 4.1 31 7 3
549 2.7 23 8 6.5
Animals received intermittent low-dose MPTP as indicated in Figure 1. The total dose of MPTP received by each animal, total time since first treatment, the time
between the last dose and animal sacrifice, and the clinical score at sacrifice is indicated.
Figure 1 MPTP treatments and clinical score of monkeys. The rhesus monkeys were treated with MPTP at the time points indicated by the
color-coded asterisks. Doses were given on two consecutive days at the amounts (in mg/kg) indicated under the asterisks. The Kurlan rating
score (rating the animal’s posture, gait, tremor, general mobility, hand movements, climbing, holding food, eating, balance, gross motor skills,
and defense reaction) is given for each monkey over time. Untreated control animals and animals before MPTP treatment had values of 0
(normal), higher values indicate increased deficiency. Daggers indicate time of sacrifice of each animal.
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normal conditions. Normal levels of Cat D have the
ability to digest > 95% of total brain protein within 24
hr under in vitro conditions [19], implicating that the
leakage of lysosomal compartments can have profound
deleterious effects on the cell itself and if released out-
side the cells would effect the surrounding brain milieu.
To investigate the relationship of Cat D to lysosomes in
the brains, we performed double immunofluorescence
for Cat D and LAMP-2, a marker for lysosomes. As
seen in Figure 5A (upper), normal neurons contain a
few lysosomes in the neuronal cell body and Cat D is
localized with the lysosomes. However in the MPTP-
treated monkey CN sections (Figure 5A lower), we see a
drastic increase in the number of lysosomes throughout
the neuronal cell body as well as in Cat D immunoreac-
tivity. Quantification reveals an average of four-fold
increase in lysosomes (Figure 5B). Given this increase,
we next questioned whether increased lysosomal biogen-
esis could arise from overexpression of Cat D.
Changes in Cat D and lysosomes due to Cat D
overexpression
To investigate the effect of increased Cat D in neurons,
we overexpressed human C-terminal GFP-tagged Cat D
(Cat D-GFP) or a control GFP (green fluorescent pro-
tein) construct in the BE-2 (M17) human neuroblastoma
cell line. Using lysotracker red as an indicator of lyso-
somes in control BE-2 cells, we observed the presence
of normal intracellular lysosomes (Figure 6A). In Cat D
transfected cells, Cat D-GFP largely co-localizes with
lysosomes, and the number of lysosomes was signifi-
cantly increased relative to controls (Figure 6A, B), con-
sistent with the findings in our in vivo model.
Cat D is present extralysosomaly and extracellularly
We next asked if we could detect Cat D enzyme activity
in the cytosol and extracellularly. We performed cytoso-
lic fractionation from cellular organelles (Additional file
1) using BE-2 cells, either non-transfected, transfected
with GFP alone, or transfected with Cat D-GFP. The
Cat D expression as well as activity were measured in
cytosolic extracts and in the culture supernatants of the
Cat D transfected cells was indeed significantly greater
when compared to controls. The active/mature form of
Cat D was detected in cytosol (Figure 6C upper panel).
Cat D activity assay showed an increase in Cat D activity
in the cytosolic fractions as well (Figure 7A, B). Not
only can the presence of cytosolic Cat D be deleterious
Figure 2 Loss of dopaminamergic nerve terminal markers in the striatum of MPTP treated monkeys. (A) Immunohistochemical staining
reveals strong staining of striatal sections of control brains (left panel: top and middle) for tyrosine hydroxylase and dopamine transporter;
whereas, MPTP administered monkey striatal sections (right panel: top and middle) show a minimal staining. The bottom panels are sections
stained with luxol fast blue. The images are unmagnified scans of the slides. (B) Immunohistochemical staining reveals strong staining of striatal
sections a control brains (left) for TyH and DAT; whereas, in an MPTP administered monkey, striatal sections (right) show minimal staining,
Bar = 20 µm. The images are representative of the monkeys in each group.
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to the cell itself but the presence of extracellular Cat D
could be lethal to the surrounding cells. Thus, we subse-
quently questioned if Cat D expression triggered cell
death.
Overexpression of Cat D leads to caspase activation and
apoptosis
To investigate whether Cat D overexpression induces
pathways leading to neuronal death, we first performed
a lactate dehydrogenase (LDH) assay on the culture
supernatant, assessing loss of plasma membrane integ-
rity. Figure 8A shows that there is a significant amount
of LDH-release caused by overexpressing Cat D in rat
striatal neurons when compared to controls. We next
performed a fluorescence live imaging assay using the
cell-permeable fluorescein isothiocyanate (FITC) conju-
gate of the caspase inhibitor VAD-FMK. This inhibitor
irreversibly binds to the activated caspase, allowing for
the in situ labeling of cells in which the caspase activa-
tion cascade has been initiated. As seen in Figure 8B,
when compared to control, the Cat D transfected rat
striatal neurons show a greater labeling for caspases,
likely due to initiation of apoptosis. Interestingly, cas-
pase activation is also seen along the neurites in Cat D
transfected cells (see Figure 8B) indicating neuronal
damage.
To evaluate the presence of apoptotic cells, Cat D-
GFP transfected and control BE-2 cells were stained
with Hoechst stain (Figure 9A). The fragmentation of
nuclei was clearly observed in Cat D transfected cells
when compared to controls. To further strengthen our
observation, we performed an in situ TUNEL assay. As
seen in Figure 9B, fragmented DNA in Cat D trans-
fected cells was clearly labeled. Also, since we found
caspase activation, we looked for cytosolic release of
Cytochrome C (Cyto-C), an activator for apoptosis. As
seen in Figure 9C, there was a clear cytosolic mobiliza-
tion of Cyto-C in Cat D overexpressing cells confirming
its release, which is strongly linked to activation of the
apoptotic pathway.
Discussion
In human PD a major unmet challenge has been to curb
the progression of disease that can affect the higher cog-
nitive functions of the patient. The molecular triggers
that induce the progression of disease to areas like the
CN and that contribute to associative and executive cog-
nitive functions are currently unknown [2,20,21]. Using
a nonhuman primate model of PD, we report for the
first time that lysosomal instability and alterations in a
lysosomal protease, Cat D, in CN can lead to degenera-
tion and dysfunction of neurons (Figure 10).
In the chronic MPTP model of PD, we first found a
significant upregulation of Cat D in the CN. Importantly,
Figure 3 Cat D is upregulated in MPTP caudate nucleus. (A)
Taqman qRTPCR for Cat D mRNA was performed on RNA from
caudate samples. A significant upregulation in Cat D mRNA is seen.
The delta Ct (dCt) method was performed to determine relative
concentrations, using the average of the Ct of 18S and GAPDH as
the normalizing value. Mean and standard error of the mean shown,
significance is indicated by *p < 0.05 (Student’s t-test). (B)
Photomicrographs of representative sections of caudate of two
animals (#1, #2) from each group of the control and MPTP monkeys.
Caudate sections were immunohistochemically stained with anti-Cat
D. Minimal staining is seen in sections from control animals (bar =
50 µm) and in corresponding increased magnification (40×, bar =
10 µm); whereas, in MPTP treated animal, there is increased staining.
Increased magnification (40×, bar = 10 µm) reveals that the staining
is seen within neurons in the cell body, axon hillock (bottom right).
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Figure 4 Double immunofluorescence of CatD with MAP2 and IBA1 in CN od MPTP monkey. (A) Double immunostaining was performed
on MPTP CN sections with the neuronal marker anti-MAP2 (red) and anti-Cat D (green). The merged image illustrates a co-localization of Cat D
with MAP2, confirming its presence in neurons. Bar = 20 µm. Higher magnification of single neuron is also provided (bottom panel, Mag). Bar =
5 µm. (B) Double immunostaining was performed on MPTP CN sections with the microglial marker anti-IBA1 (red) and anti-Cat D (green). The
merged staining of Cat D with IBA1 conforms the absence of Cat D in microglial cells. Bar = 20 µm. Higher magnification (bottom panel, Mag).
Bar = 5 µm.
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Figure 5 Lysosomal localization of Cat D. (A) Double immunostaining was performed on control and MPTP CN sections with anti-Cat D
(green) and the lysosomal marker anti-LAMP2 (red). The merged image (right panel) illustrates a co-localization of Cat D with LAMP2, its increase
in sections from MPTP treated animals. Bar = 20 µm. (B) Quantification of lysosomes was performed on sections, n = 10 neurons for each animal
were examined, unpaired t-test was performed on the average lysosomes quantified from the three control (Mean ± SEM: 27.8 ± 0.89) and three
MPTP (Mean ± SEM: 110.8 ± 4.5) animals, p < 0.001.
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Figure 6 Overexpression of Cat D in BE-2 cells. (A) BE-2 neuroblastoma cells were either transfected with GFP (control) or with Cat D-GFP
and lysosomes stained with lysotracker red. The GFP expressing BE-2 cells (left panels (LysT-Red, GFP-merge), bar = 5 µm) show few lysosomes
localized inside the cell body (see Lysotracker red (LysT-red) panels); whereas, the Cat D-GFP transfected cells (right panels (LysT-Red, CD-merge),
bar = 5 µm) show build up of lysosomes (see Lysotracker red (LysT-red) panels). GFP-merge and CD-Merge represent the corresponding merged
images with green channel. (B) Quantification of lysosomes was performed on BE-2 cells transfected with either GFP or Cat D (n = 10 cells for
each group). Unpaired t-test, p < 0.001 (C) Western blot showing the expression of Cat D (~30 kDa, the mature Cat D heavy chain) in non-
transfected (control) and transfected (Cat D) BE-2 cells. b-actin was used as loading control. Lower bar graph is representative of 3 individual
experiments. Mean and standard error of the mean shown, significance is indicated by ***p < 0.001.
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we also observed that there is an increased staining for
Cat D in neurons, and an increase in the number of lyso-
somes in neurons in MPTP-induced PD. In vitro we
found that Cat D overproduction itself led not only to
increased lysosomal biogenesis but also led to the occur-
rence of extralysosomal (including extracellular) Cat D
and caspase activation leading to the activation of apop-
totic pathway.
While the trigger for increased Cat D production is
not known, it has been shown that in order to compen-
sate for the loss of DA in PD, an increased rate of DA
Figure 7 Cat D is present outside of lysosomes. Fluorometric
assay for cathepsin was performed on BE-2 neuroblastoma cell
cytosolic extracts (Figure 6A) and on culture supernatants (Figure
6B) transfected with either GFP or Cat D, or non-transfected (NT).
Relative fluorescence unit (RFU) per µg protein is calculated by
normalizing the fluorescence signal to the amount of protein
present in each sample. The experiments are representative of n =
3. Mean and standard error of the mean shown, significance is
indicated by ***p < 0.001.
Figure 8 Cat D overexpression leads to release of lactate
dehydrogenase (LDH) and caspase activation. (A) LDH assay was
performed on the rat striatal neurons transfected with either vehicle
alone or Cat D. For positive control, 2% Triton X-100 and
staurosporine treatments were performed. Cat D overexpression
significantly increased the amount of LDH in media. The experiment
is representative of n = 4. Mean and standard error of the mean
shown, significance is indicated by ***p < 0.001. (B) Live imaging
performed on rat striatal neurons. Neurons were transfected with
Cat D and stained for CaspACE FITC-VAD-FMK in situ marker. The
green staining represents the activation of caspase and apoptosis.
As seen, compared to control the Cat D transfected neurons show a
clear activation in FITC caspase levels, including in neurites (boxed
area in lower left panel enlarged in lower right, see processes on
neuron marked by asterisk). Staurosporine treated neurons were
used as a positive control. Bar = 50 µm.
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turnover takes place in the striatum, especially in the
CN. Therefore, these hyperactive neurons are prone to
more oxidative stress [4]. Intriguingly, oxidative stress is
thought to activate lysosomes and release Cat D into the
cytosol in non-neuronal cells [22-26]. Although oxida-
tive stress has been described as a main trigger for the
loss of DA neurons in SN pars compacta region in PD
[27], its link to PD-related changes in other parts of the
brain are less well studied. A complete breakdown of
lysosomes and release of high concentrations of lysoso-
mal enzymes can lead to necrosis; whereas partial or
selective release of lysosomal proteases could trigger
apoptosis [28]. Studies in non-neuronal cells have
shown that lysosome membrane permeabilization fol-
lowed by Cat D release are actually important events in
the death cascade and occurs downstream of the Bax-
Figure 9 Cat D overexpression leads to apoptosis. (A) Hoechst staining was performed on BE-2 neuroblastoma cells transfected with or
without Cat D. Cat D overexpression clearly indicates fragmentation of nucleus in Cat-D GFP cells (see white arrow). The experiment is
representative of n = 4. Bar = 5 µm (B) In situ measurement of apoptosis in Cat D transfected BE-2 neuroblastoma cells. As seen, the CY-5
staining in nucleus can be strongly visualized in Cat D transfected cells but not in control cells indicating the presence of fragmented DNA in
Cat D. The experiment is representative of n = 4. Bar = 5 µm (C) Protein extracts from mitochondrial and cytosolic fractions, isolated from Cat D
transfected and control cells, were blotted for Cyto-C, GAPDH, Tom20 and b-actin. As can be seen from western blot, there is clear increase in
cytosolic presence of Cyto-C in Cat D transfected cells compared to controls, whereas another mitochondrial marker (Tom20) as well as a
cytoplasmic marker (GAPDH) remain similar, indicating an activation of apoptotic pathway.
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dependent caspase mechanism [29] linking the apoptotic
machinery to neuronal loss in our study.
Cell death has been extensively examined in PD, but
most of these studies relate to direct DA neuronal loss
in the SN pars compacta region, the initiating site of
disease [30]. However, we examined the CN, which is
not the direct site of injury caused by MPTP but is
affected by the progression of disease. Here, we identify
the activation of lysosomal pathways as pathogenic in
the CN.
Intriguingly, not only was Cat D upregulated in neu-
rons but also was seen to be present in the cytosol and
extracellularly, a phenomenon that has not been exam-
ined until now in PD or its models. By overexpressing
Cat D in human neuroblastoma cells or in rat striatal
neurons, we see a similar phenomenon. The deleterious
effects of protease leakage in particular, Cat D, into the
extracellular environment has been best addressed in
breast cancer research where studies indicated that the
extracellular matrix was degraded by Cat D released
from cancer cells into an acidic microenvironment con-
sequently facilitating tumor invasion [31]. Cancer related
studies have also revealed that the presence of cytosolic
CD stimulates apoptotic pathways by interacting with
members of the apoptotic machinery [32]. Recently, stu-
dies also suggest that pro-cat-D secreted by epithelial
cancer cells promotes fibroblast outgrowth in a para-
crine LRP1-dependent manner in the breast tumor
microenvironment [33].
There is precedence for demonstration of extralysoso-
mal Cat D in neurodegeneration. Trimethyltin chloride
(TMT) is a potent neurotoxic agent. TMT was shown
to upregulate Cat D in neurons both in vivo and in
vitro, and following TMT treatment of rats Cat D is pre-
sent in the neuronal cytoplasm, and linked to apoptosis
[34]. Gaucher’s disease is the most common form of
lysosomal storage disorders, results in profound neuro-
nal damage, and can be modeled in glucosylceramidase
knockout mice. In neurons of such mice Cat D is upre-
gulated and present in the cytosol, and its presence
linked to neuronal damage [35]. Alzheimer’s disease is
the most prevalent neurodegenerative disorder, and
aspects can be mimicked in transgenic mice through the
expression of mutant forms of amyloid precursor pro-
tein in neurons, resulting in intraneuronal amyloid beta
accumulation. This again is accompanied by Cat D leak-
age from lysosomes into the cytoplasm [36].
While our study as well as these support the mechan-
ism that Cat D leakage leads to activation of apoptotic
pathway and then cell death, we cannot exclude that
Cat D leakage itself can lead to other causes of cellular
destruction such as through proteolysis. Lysosomal
membrane permeabilization, which includes leakage of
Cat D, can result in an apoptotic death as well as cell
death that has a subapoptotic or necrotic characteristic
[37]. Furthermore there is the possibility that the Cat D
leakage is a result of neuronal damage, and not its
cause. Although our in vitro experiment does not
directly address the cause of the leakage phenomenon in
vivo, the increased Cat D mRNA as well as protein
expression definitely is indicative of dysregulated lysoso-
mal pathways, and this could be addressed more effec-
tively in additional animal studies in the future. While
cognizant of these caveats, our data provides evidence
that leakage of Cat D can be the cue for spread of dis-
ease to other regions of the brain in PD.
While others have suggested that increasing expres-
sion of Cat D could be used as a therapeutic strategy
in PD as it clears toxic a -synuclein aggregates [38],
our data clearly indicate that over-production or
increased Cat D levels in neurons can lead to neuronal
injury, raising caution to this approach, as well as pro-
viding pathogenic clues to the progressive neuronal
damage in PD.
Figure 10 Schematic representation of disease progression in
the caudate. (A) Depiction of the neuronal pathways involved in
normal brain functioning, glutamatergic as well as dopaminergic
innervations from cortex and substantia nigra (SN) to the caudate
nucleus. (B) MPTP and PD affects the neurons in SN leading to loss
of the dopaminergic projections to the caudate, leading to
dysregulation of lysosomal pathways, and increasing the number of
lysosomes as well as Cat D and extralysosomal Cat D. (C) Slow but
persistent damage resulting from upregulation of Cat D expression
and leakage leads to neuronal dysfunction and death through
apoptosis or other mechanisms.
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Conclusions
In conclusion, our study provides strong evidence that
Cat D can be involved in the long-term neuronal
damage in PD in regions remote from the site of pri-
mary insult, and underscores the need to study brain
regions outside the sites of initial damage in neurode-
generation to help understand the basis of disease pro-
gression. Therefore, this study provides new avenues for
therapeutic interventions that might help to treat or
arrest the progression of motor and cognitive disorders
commonly seen in human PD patients.
Materials and methods
Animals
Adult (6-8 years of age) male rhesus monkeys served as
subjects or controls for this study. Monkeys, free from
SIV (simian immunodeficiency virus), type D simian ret-
rovirus, and herpes B virus were obtained from Covance
(Alice, TX, USA) and Valley Biosystems, Inc. (Sacra-
mento, CA, USA). Animals were kept in a biocontain-
ment facility and housed individually in stainless-steel
cages, which permitted olfactory, visual, and auditory
contact with other monkeys in the room. Monkeys were
paired housed during several hours of the day, which
permitted animal interaction and evaluation of social
behavior. The room was maintained on a 12/12 hr light/
dark cycle (lights on 0600; lights off 1800) and at a tem-
perature of 25 ± 1°C. Monkeys had previously been
trained on a BMS task as previously described [39]. The
task was designed to test bimanual motor coordination,
procedural learning and motivation to work for a pre-
ferred food (raisins). Due to the hazardous nature of
MPTP, the treated animals (#543, #547 and #549) were
kept together in a separate room in the facility. The
control animals (#516, #517 and #546) did not receive
vehicle injections; they did receive ketamine injections
for blood draws. The controls were chosen to be of
equivalent age as the experimental group.
MPTP treatment of nonhuman primates
MPTP hydrochloride (Sigma-Aldrich, St. Louis, MO,
USA) was dissolved in sterile saline and given intramus-
cularly to lightly anesthetized (5 mg/kg ketamine) rhesus
monkeys on two consecutive days at an initial dose of
0.4 mg/kg. For clinical rating of Parkinsonism, the Kur-
lan scale was used in which monkeys were rated daily
on weekdays for posture, gait, tremor, general mobility,
hand movements, climbing, holding food, eating, bal-
ance, gross motor skills, and defense reaction as
described [17] in addition to BMS. Animals were tested
until recovery from acute effects of MPTP were deter-
mined by a stable rating score and were evaluated for
the next round of dosing, which was given at doses of
0.3-0.4 mg/kg. The time scale of dosing is indicated in
Figure 1, and the overall amount given to each animal is
listed in Table 1.
All experiments were performed under the approval of
the Environmental Health and Safety Department, the
Institutional Biosafety Committee and the Institutional
Animal Care and Use Committee of The Scripps
Research Institute, following NIH guidelines.
RNA isolation and Quantitative Real Time PCR
The CN was dissected from the brains, snap frozen, and
RNA isolated using Trizol (Invitrogen, Carlsbad, CA,
USA). RNA was quantified and determined to be of
good purity by spectrophotometric analysis on a Nano-
Drop 8000 (Thermo Scientific, Wilmington, DE, USA).
To check the integrity, RNA samples were run on the
Bioanalyzer 2100 (Agilent Technologies, Santa Clara,
CA, USA). The RIN values in the range of 7-9 for the
RNA samples were indicative of good quality.
Two micrograms of RNA from the CN of control and
MPTP monkeys were used for reverse transcription. In
a 50 µL reaction, reverse transcription (RT) was carried
out using the Superscript kit (Invitrogen) for 1 hr at 42°
C, followed by 70°C for 5 min to inactivate the RT
reagents. RNase H (New England Biolabs, Beverly, MA,
USA) treatment was then performed at 37°C for 20 min.
An equal volume of RNase and DNase free water was
then added to the reactions.
Real time PCR was performed using gene-specific pri-
mers and probes. The primers and probe sequences
were designed for rhesus sequences using the Gene-
script online tool http://www.genescript.com and
obtained from Eurogentec (San Diego, CA, USA). The
sequences of the primers and probe for 18S and
GAPDH controls have been previous reported [40];
whereas, the ones for Cat D were based on the rhesus
Cat D sequence (GenBank accession XM_001091601.2):
forward primer ACTGCAAACTGCTGGACATC,
reverse primer CGTAGTGGATGGCAAATGAG, probe
CAGCGACAAGTCCAGCACCTACG. Dilution analysis
was carried out using monkey spleen cDNA on all the
primers used for the study. The resulting Ct values indi-
cated good linearity over the dilutions, with R2 values
ranging from 0.994 to 0.998, and the efficiencies calcu-
lated from the slopes were from 95 to 100%.
To carry out quantitative real time PCR, 2 µL of the
(1:10 diluted) cDNA was used for assaying the amount
of 18S endogenous rRNA; 5 µL (undiluted) each for all
other genes. All reactions were performed in duplicates,
12.5 µL of Taqman gene expression master mix
(Applied Biosystems, Foster City, CA, USA) was added
per 25 µL reaction. The reaction mixture was brought
to a final concentration of 5 mM MgCl2. Real time PCR
was performed in 96-well plate on a StepOnePlus real
time PCR system (Applied Biosystems). The delta Ct
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(dCt) method was performed to determine relative con-
centrations using the average of the Ct of 18S and
GAPDH as the normalizing value. Relative units (2dCt)
were calculated and used as a measure of mRNA
expression. Unpaired student’s t tests (GraphPad Prism
Software, San Diego, CA, USA) were used for statistical
analyses.
Immunohistochemistry and Double Immunofluorescence
Formalin-fixed, paraffin-embedded tissue blocks con-
taining the striatum (caudate nucleus and putamen)
were sectioned at 5 µm thickness and picked up on
glass slides. For immunohistochemistry, following
deparaffinization, antigen retrieval was performed by
heating to 95°C in 0.01 M citrate buffer, pH 6.39, for
40 min, then left for 20 min to steep. Sections were
blocked in 0.5% casein, followed by the addition of
either 1:1000 dilution of an antibody to TyH (Milli-
pore, Billerica, MA, USA), 1:1000 dilution of an anti-
body to DAT (Millipore) or 1:50 dilution of an
antibody to Cat D (Cell Signaling, Denvers, MA, USA)
overnight at 4°C. Following washes, signal was detected
using the SuperPicture broad spectrum secondary anti-
body-horseradish peroxidase polymer reagent (Invitro-
gen) and developed with the 3,3’-Diaminobenzidine
(DAB) (Vector Laboratories, Burlingame, CA, USA),
followed by a hematoxylin counterstain (Invitrogen)
and examined microscopically (Zeiss inverted micro-
scope, Carl Zeiss, NY, USA).
For double immunofluorescence, sections were depar-
affinized, antigen retrieval was performed by heating to
95°C in 0.01 M citrate buffer, pH 6.39, for 40 min, then
left for 20 min to steep. Sections were blocked in 20%
BSA, followed by the addition of a 1:50 dilution of rabbit
polyclonal anti-Cat D antibody (Cell Signaling) overnight
at 4°C. Following PBS washes, sections were incubated in
chicken anti-rabbit Alexa-Flour 488 secondary antibody
(Invitrogen) for 1 hr, followed by blocking in 20% BSA
and incubation with 1:100 dilution of rat monoclonal
anti-LAMP2 antibody (Abcam, Cambridge, MA, USA)
overnight at 4°C. Following washes, sections were incu-
bated in goat anti-rat Alexa-Flour 568 secondary anti-
body (Invitrogen) for 1 hr followed by final washes,
mounting in Prolong gold anti-fade with DAPI (Invitro-
gen). For MAP2 double staining, following staining and
detection of Cat D, mouse monoclonal anti-MAP2
(Sternberger Monoclonals, Covance, Princeton, NJ, USA)
antibody was used in conjunction with goat-anti-mouse
Alexa-Flour 568 secondary antibody (Invitrogen). For
microglial double immunofluorescence, the above stain-
ing protocol was followed, except using mouse monoclo-
nal anti-Cat D (Abcam) followed by goat-anti-mouse
Alexa-Fluor 568 as a secondary antibody, and rabbit
polyclonal anti-IBA1 (Wako, Richmond, VA, USA)
followed by goat-anti-rabbit Alexa-Fluor 488 secondary
antibody (Invitrogen). We interchanged the IBA1 color
to red and Cat D to green using the AxioVision REL 4.8
Software (Carl Zeiss, NY, USA) so that the images appear
consistent throughout the panel.
Quantification of lysosomes
Images were taken as z-stacks at 63 × for larger magnifi-
cation. A single neuron was selected from the image,
and a final merged image was generated (Cat D/
LAMP2). The number of round lysosomes in each plane
of the z-stack was quantified using a manual counting
system recommended by the software. Each plane was
scanned for presence of lysosomes, which might be
overlayed or hidden in different planes. To prevent
duplication, the software generates an identification
number for each lysosome. To allow the end-user to
accurately determine the presence of a single large vesi-
cle or multiple small ones, double-labeled lysosomes
were quantified geometrically as well as densitometri-
cally. Quantification was performed using imaging pro-
gram, AxioVision REL 4.8 Software (Carl Zeiss, NY,
USA). The data were analyzed in Graphpad Prism
(GraphPad Software, La Jolla, CA, USA).
Cell culture
Human neuroblastoma BE-2 (M17) cells (American
Type Culture Collection, Manassas, VA, USA) were cul-
tured under sterile conditions in Dulbecco-modified
Eagle medium (LONZA BioWhittaker, Portsmouth, NH,
USA) supplemented with 10% fetal calf serum, penicillin
(100 units/ml), and streptomycin (100 µg/ml) in 5%
CO2 humidified atmosphere at 37°C.
For isolation of primary rat neurons, embryonic
(gestational day 18) rat striatum was purchased from
Brain Bits LLC (Springfield, IL, USA). Neuronal cultures
were prepared by dissociating the tissue with 0.25%
trypsin for 30 min, neutralized with 10% fetal bovine
serum, and further dissociating by triturating. The
resulting single-cell suspension was centrifuged (1000
rpm/5 min) and was cultured on poly-D-lysine coated
plates in Neurobasal media containing 0.5 mM l-gluta-
mine, 50 µg/ml penicillin and streptomycin and supple-
mented with B27 (Invitrogen). The striatal neurons were
grown for 11 days in vitro (DIV) and were stained with
anti-TyH (Millipore) and anti-DAT (Millipore) to con-
firm purity.
Transfections and imaging of rat striatal neurons and BE-
2 (M17) cells
After DIV 11 in culture, the rat striatal neurons were
transfected with 1 µg human Cat D tagged with GFP at
the carboxy-terminus (Origene Technologies, Rockville,
MD, USA) or a GFP-only vector (Origene) by NeuroMag
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according to manufacturer’s protocol (OZ Biosciences,
Marseille, France). Neurons were cultured for 48 hr after
transfection and checked microscopically for GFP
expression.
Transfection of BE-2 (M17) cells were done using
Fugene 6 (Roche Applied Science, Indianapolis, IN,
USA) as per manufacturer’s instructions. After transfec-
tions, cells were fixed with 4% PFA for 15 min. Double
immunoflourescence was performed on the lysotracker
treated cells; cells were washed 3 times with 1× PBS for
5 min each wash. Cells were blocked in 10% normal
goat serum, followed by the addition of a 1:50 dilution
of rabbit polyclonal anti-Cat D antibody (Cell Signaling)
overnight at 4°C. Following washes, cells were incubated
in goat anti-rabbit Alexa-Flour 488 secondary antibody
(Invitrogen) for 1 hr followed by final PBS washes,
mounting in Prolong gold anti-fade with DAPI (Invitro-
gen). Double-labeled lysosomes were quantified as
described in this methods section.
Cathepsin D (Cat D) enzyme activity
Cat D activity was measured in cytosol and in cell cul-
ture supernatants of BE-2 (M17) cells transfected with
Cat D. Cytosol was prepared by lysing cells in a hypo-
tonic buffer (0.32 M sucrose, 10 mM Pipes pH 7.4, 0.1
M NaCl, 3 mM MgCl2, 5 mM EDTA and 0.5% Triton
X-100). Cell debris and nuclei were spun down at a low
speed, 800 × g for 10 min, and the supernatants were
spun at a high speed, 100,000 × g in a TLA100.4 for 1
hr. The supernatants contain the cytosolic contents, and
the pellet contains other sub-cellular organelles.
Cat D activity was measured by using a kit containing
a fluorogenic peptide substrate peptide, GKPILFFRLK
(Dnp)-DR-NH2 labeled with MCA (Abcam, Cambridge,
MA, USA). Reactions were initiated by the addition of
substrate, and kinetics of substrate hydrolysis was mea-
sured using a fluorescent plate reader (Ex 340 nm, Em
460 nm). Data were imported to Graph Pad Prism for
analysis and normalization to total protein assayed.
Lactate dehydrogenase (LDH) assay and CaspACE FITC
live-dead assay
LDH-assay was performed as per kit instructions (Cyto-
toxicity Detection Kit, Roche). Briefly, rat striatal neu-
rons were transfected with Cat D; a vehicle treated was
used as a control. As a high control, some neurons were
exchanged with assay medium containing 2% Triton X-
100, and only assay medium was measured as low con-
trol or background control. Some neurons were also
treated with 0.5 mM staurosporine (Roche), a positive
modulator of cell death. An equal amount of reaction
mixture was added to assay medium, and LDH release
was measured spectroscopically at 490 nm using a fluor-
escent plate reader.
For live imaging of apoptotic neurons, CaspACE
FITC-VAD-FMK in situ marker (Promega, Madison,
WI, USA) was used. Briefly, the transfected neurons
were incubated with 10 mM of CaspACE FITC-VAD-
FMK at 37°C for 30 min. Cells were rinsed in PBS and
examined in a fluorescence microscope (Zeiss inverted
microscope).
TUNEL staining
TUNEL staining was performed using the ApopTag Plus
Peroxidase In situ Apoptosis Detection kit (Millipore)
according to the manufacturer’s instructions with minor
modifications. Briefly, cells were fixed on coverslips with
1% paraformaldehyde, followed by washes and post-fixa-
tion for 5 min at -20°C with ethanol:acetic acid (2:1),
followed by PBS washes. Samples were oxidized for 5
min with 3% H2O2 in PBS to reduce endogenous perox-
idase activity and then washed with PBS. Slides were
next prehybridized in equilibration buffer for 5 min, fol-
lowed by hybridization with terminal deoxynucleotidyl
transferase enzyme for 1 hr at 37°C. The hybridization
reaction was terminated by incubation with stop buffer
and PBS wash. HRP-conjugated anti-digoxigenin was
added next (30 min at RT), followed by PBS wash. The
signal was converted to fluorescence using TSA Cy5 kit
(Perkin Elmer, MA, USA) according to the manufac-
turer’s protocol. Coverslips were mounted in Prolong
gold anti-fade reagent with DAPI (Invitrogen).
Western blotting
SDS-PAGE electrophoresis was performed using
NuPAGE gel system (Invitrogen, Carlsbad, CA) in 4-
12% gradient gels under reducing conditions. For wes-
tern blot analyses, 10 µg of protein extracts were loaded
per lane. Nonspecific antibody binding was blocked
using 5% nonfat dried milk for 1 hr at room tempera-
ture. Immunoblotting was carried out with polyclonal
rabbit anti-Cat D (1:1000, Cell Signaling), monoclonal
rabbit anti-LAMP1 (1:1000, Cell Signaling), or polyclo-
nal rabbit anti-b-actin (1:5000, Thermo Fisher Scienti-
fic); followed by secondary antibody (1:20,000 HRP-
conjugated anti-rabbit IgG; Thermo Fisher Scientific).
Blots were developed with 1:1 solution of Super Signal
West Pico Chemiluminescent Substrate and Luminol/
Enhancer (Thermo Fisher Scientific, Rockford, IL, USA).
Additional material
Additional file 1: Figure S1.
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